2. Signaling Pathways
  3. Anti-infection
  4. HBV

HBV

Hepatitis B virus

HBV

Related Products

PDF 0.42 MB

HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-149435
    HBV-IN-36
    		Inhibitor
    HBV-IN-36 (compound 42) is a HBV inhibior (IC50=2 μM), showing anti-HBV activity with EC50 of 0.58 μM.
    HBV-IN-36
  • HY-148201
    Oleana-2,12-dien-28-oic acid
    		Inhibitor 99.88%
    Oleana-2,12-dien-28-oic acid is an HBV-DNA inhibitor, HBsAg and HBeAg inhibitor. Oleana-2,12-dien-28-oic acid can be used in hepatitis B virus infection disease research.
    Oleana-2,12-dien-28-oic acid
  • HY-144045
    HBV-IN-14
    		Inhibitor
    HBV-IN-14 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-14 is a pyridinopyrimidinones compound. HBV-IN-14 has the potential for the research of HBV infection (extracted from patent WO2021190502A1, compound 5).
    HBV-IN-14
  • HY-116001B
    (-)-Carbovir
    		Inhibitor
    (-)-Carbovir is an active compound.
    (-)-Carbovir
  • HY-111073
    Bentysrepinine
    		Inhibitor
    Bentysrepinine (Y101) is an orally active HBV inhibitor with anti-hepatitis B virus infection activity. Bentysrepinine exhibits favorable pharmacokinetic characteristics, with absolute bioavailability of 44.9%, 43.1%, and 19.2% in rats, dogs, and monkeys, respectively, and it does not accumulate in monkeys after 90 days of oral administration. Bentysrepinine is under research in the antiviral and hepatitis fields.
    Bentysrepinine
  • HY-145059
    HBV-IN-12
    		Inhibitor
    HBV-IN-12 is a potent hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). HBV-IN-12 shows anti-HBV DNA activity (0.001 μM＜EC50 ≤0.02 μM). From patent WO2021204252A1, compound 15.
    HBV-IN-12
  • HY-147863
    HBV-IN-24
    		Inhibitor
    HBV-IN-24 (compound (2ʹS, 6S)-1a) is a potent HBV inhibitor. HBV-IN-24 exhibits potent inhibition activity against HBV DNA, HBsAg, and HBeAg, with EC50 values of 0.6, 0.6, and 4.6 nM, respectively. HBV-IN-24 shows excellent antiviral activity, could have improved neurotoxicity.
    HBV-IN-24
  • HY-146394
    HBV-IN-22
    		Inhibitor
    HBV-IN-22 (Compound LC5f) is an inhibitor of HBV DNA replication with IC50 values of 0.71 μM and 0.84 μM against wild-type and agent resistant HBV strains, respectively.
    HBV-IN-22
  • HY-N3093
    Periglaucine B
    		Inhibitor
    Periglaucine B ((+)-Periglaucine B) is an alkaloid and an HBsAg inhibitor. Periglaucine B can be isolated from Pericampylus glaucus. Periglaucine B inhibits the secretion of hepatitis B virus (HBV) surface antigen (HBsAg) in Hep G2.2.15 cells with an IC50 of 0.47 mM.
    Periglaucine B
  • HY-120377
    CYP1A1 inhibitor 8a
    		Inhibitor
    CYP1A1 inhibitor 8a is a compound that potently and selectively inhibits the CYP1A1 enzyme and has the potential to prevent cancer. CYP1A1 inhibitor 8a exhibits more than 10-fold selectivity for CYP1A1 and more than 100-fold selectivity over other enzymes in the CYP1 subfamily. CYP1A1 inhibitor 8a can effectively antagonize B[a]P-mediated activation of the aryl hydrocarbon receptor (AhR) in yeast cells and protect human cells from CYP1A1-mediated B[a]P toxicity. CYP1A1 inhibitor 8a has the potential to be developed as a cancer chemopreventive agent.
    CYP1A1 inhibitor 8a
  • HY-B0250S1
    Lamivudine-13C,15N2,d2
    		Inhibitor
    Lamivudine-13C,15N2,d2 (BCH-189-13C,15N2,d2) is a 13C, 15N, and deuterium labeled Lamivudine (HY-B0250). Lamivudine is an orally active and blood-brain barrier permeable nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine inhibits HIV reverse transcriptase 1 and 2 and hepatitis B virus (HBV) reverse transcriptase.
    Lamivudine-<sup>13</sup>C,<sup>15</sup>N<sub>2</sub>,d<sub>2</sub>
  • HY-145049
    HBV-IN-6
    		Inhibitor
    HBV-IN-6 is a potent HBV inhibitor with an EC50 of 44 nM (WO2021213445A1, compound 3).
    HBV-IN-6
  • HY-P4045
    HBV Seq2 aa:208-216
    HBV Seq2 aa:208-216, a HBsAg derived CD8 epitope peptide, is studied as part of Large envelope protein from Hepatitis B virus.
    HBV Seq2 aa:208-216
  • HY-149468
    Antiviral agent 38
    		Inhibitor
    Antiviral agent 38 (compound 2.1-1) is a potent antiviral agent. Antiviral agent 38 can be used for hepatitis B virus (HBV) research.
    Antiviral agent 38
  • HY-156702
    HBV-IN-38
    		Inhibitor
    HBV-IN-38 (Example 193) is an HBV DNA inhibitor (EC50≤100nM). HBV-IN-38 can be used to study viral infections.
    HBV-IN-38
  • HY-161605
    HBV/HDV-IN-2
    		Inhibitor
    HBV/HDV-IN-2 (Compd 143) is a HBV, HDV and PD-1/PD-L1 inhibitor, with an EC50 of 35 nM for T cell activation.
    HBV/HDV-IN-2
  • HY-121850
    Rolicyprine
    		Inhibitor
    Rolicyprine (EX-4883) is an antidepressant with neuroprotective activity. Rolicyprine can improve depressive symptoms and promote neuroregeneration. Rolicyprine also shows potential effectiveness for anxiety suppression.
    Rolicyprine
  • HY-162795
    HBV-IN-47
    		Inhibitor
    HBV-IN-47 (compound 4a) is a capsid assembly regulator with inhibitory activity against hepatitis B virus (HBV). HBV-IN-47 exhibits strong anti-HBV activity in HepAD38 cells with low toxicity (EC50=0.24 μM). HBV-IN-47 can be used for the study of chronic hepatitis B (CHB).
    HBV-IN-47
  • HY-N3861
    Erythrocentaurin
    		Inhibitor
    Erythrocentaurin, a natural compound, is a new class of hepatitis B virus inhibitor.
    Erythrocentaurin
  • HY-129923R
    (R)-Omeprazole sodium (Standard)
    		Inhibitor
    (R)-Omeprazole (sodium) (Standard) is the analytical standard of (R)-Omeprazole (sodium). This product is intended for research and analytical applications. (R)-Omeprazole sodium is a gastric acid resistant compound with activity to inhibit gastric acid secretion. (R)-Omeprazole sodium is metabolized in vivo, and its metabolism is primarily affected by cytochrome P450 enzymes. The interaction between (R)-Omeprazole sodium and mannitol may affect its bioavailability in formulations. (R)-Omeprazole sodium exhibits reversible direct and metabolism-dependent inhibition of CYP2C19.
    (R)-Omeprazole sodium (Standard)
Cat. No. Product Name / Synonyms Application Reactivity